This article first appeared on GuruFocus.
Release Date: November 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
AbCellera Biologics Inc (NASDAQ:ABCL) has successfully transitioned from a platform company to a clinical-stage biotech, with phase one clinical trials for ABCL 635 and ABCL 575 underway.
-
The company has initiated activities at its new clinical manufacturing facility and completed substantial platform investments.
-
AbCellera Biologics Inc (NASDAQ:ABCL) maintains a strong liquidity position with approximately $680 million in available liquidity, including cash, cash equivalents, and committed government funding.
-
The appointment of Dr. Sarah Numberg as Chief Medical Officer brings over 20 years of clinical drug development experience to the company.
-
The company is on track to advance at least one more development candidate into IND-enabling studies by the end of the year.
-
Revenue for the quarter was $9 million, which, although an increase from the previous year, is still relatively low.
-
Research and development expenses increased significantly to $55 million, reflecting a focus on internal and co-development programs.
-
The company reported a net loss of approximately $57 million for the quarter, an increase from the previous year’s loss.
-
There is a trend of decreasing research fee revenue as the company focuses more on its internal pipeline.
-
The transition from partner-initiated programs to AbCellera-led development has resulted in some delays in clinical progression.
Q: Can you explain why partner-initiated programs may not be progressing clinically and the rationale behind appointing Dr. Sarah Nunberg as CMO? A: Carl Hansen, CEO, explained that the transition from a partnership model to self-led development has led to a slower clinical progression of partner-initiated programs. The appointment of Dr. Sarah Nunberg as CMO aligns with the company’s shift to internal drug development, bringing her extensive clinical experience to advance their pipeline.
Q: What is the data disclosure strategy for the ABCL 635 Phase 1 study, and what profile would support advancing to Phase 2? A: Carl Hansen, CEO, stated that a single disclosure will be made after completing the proof of concept phase. The study aims to demonstrate safety and efficacy competitive with existing market products, with results expected around mid-next year.
